Epizyme (EPZM) Initiated with a Hold at Leerink Partners


Leerink Partners analyst Geoff Porges initiated coverage with a Hold rating on Epizyme (NASDAQ: EPZM) today and set a price target of $11. The company’s shares closed yesterday at $10.25, close to its 52-week low of $8.61.

According to TipRanks.com, Porges is a 4-star analyst with an average return of 6.2% and a 50.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Restorbio Inc, and Biogen Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $23.67 average price target.

See today’s analyst top recommended stocks >>

Based on Epizyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12 million and GAAP net loss of $29.13 million. In comparison, last year the company earned revenue of $10 million and had a GAAP net loss of $28.02 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Develops therapeutics for the treatment of patients with genetically defined cancers

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts